The Pharma Letter | Saxagliptin may pose heart failure risk Clinical Advisor In a statement, the agency said that the probe was spurred by "a study published [last September] in the New England Journal of Medicine, which reported an increased rate of hospitalization for heart failure." The NEJM study did not find that ... FDA looks at possible heart failure link with AZ's Onglyza FDA to review heart failure risk with AstraZeneca diabetes drug FDA Investigating Heart Failure Risk Linked To Onglyza |
